NASH (Non -Alcoholics Steatohepatitis) Market: Trends, Opportunities and Forecasts (2015-2030) (By Region, By Drugs – Off Label & Special Treatment Drugs, Aramachol, Clinical Pipeline, GR-MD-02, GFT 505 Market)

The Global NASH Market is growing at a moderate rate over last five years on account of rising number of obesity among young population. NASH (non-alcoholic steatohepatitis) is a large, un-tapped market with no FDA approved therapeutics. Antioxidants, anti-diabetic medications, anti-obesity medications and antihyper Lipidemics are some of the off-label products currently used by NASH patients. Moreover, increase in number of patients suffering from fat in liver disorder is further anticipated to boost the Global NASH market in the coming years.

According to Azoth Analytics research report, "Global NASH (Non -Alcoholics Steatohepatitis) Market: Trends, Opportunities and Forecasts (2015-2030) - (By Region, By Drugs - Off Label & Special Treatment, Aramachol, Clinical Pipeline, GR-MD-02, GFT 505 Market)", global non-alcoholic steatohepatitis drug specific market is estimated to start growing by 2020 at a CAGR of 25.56% during 2020-2030, due to the projected product launches in 2020. Surge in cycles of clinical trials and their success rate has improved the probability of industries receiving commercial approval for NASH therapeutics by the end of 2020. Additionally, the absence of efficient diagnostic technologies acts as a major hurdle for the research of NASH therapeutics. Nevertheless, the emergence of novel biomarker technologies and improvements in liver biopsy technologies are expected to bring about an evolution in the diagnosis of NASH and other fatty liver diseases. Despite of these challenges, certain key players such as Galmed Pharmaceuticals, Gilead Sciences, Novo Nordisk, Genfit, Intercept and Galectin Therapeutics are conducting extensive research on NASH therapeutics and are receiving positive results from clinical trials. But, the low diagnosis rates, low prescription rates and low treatment seeking rates continue to pose significant challenges for these emerging players. The United States, which has the highest number of research initiatives concerning NASH, holds nearly half of the global market share. The chief reason behind this growth is the high prevalence of diabetes and obesity and the growing number of people suffering with these conditions. The US has the highest number cases of NASH and other non-alcoholic fatty liver diseases.
Request a Free Sample copy at http://www.reportsweb.com/inquiry&RW000187686/sample

Scope of the Report
Global NASH (Non -Alcoholics Steatohepatitis) Market: Trends, Opportunities and Forecasts (2015-2030) - (By Region, By Drugs - Off Label & Special Treatment Drugs, Aramachol, Clinical Pipeline, GR-MD-02, GFT 505 Market) analyses the following aspects of global Alzheimer's market:
- Global NASH Market Size, Share & Forecast
- Segmental Analysis - By off Label , By Specific Drug and By Patient
- Policy & Regulatory Landscape
- Changing Market Trends & Emerging Opportunities
- Competitive Landscape & Strategic Recommendations

Complete report is available at http://www.reportsweb.com/global-nash-non--alcoholics-steatohepatitis-market

Why You Should Buy This Report?

1. To gain an in-depth understanding of NASH disease and dementia market propelling globally.
2. To identify the on-going trends and anticipated growth in the next five years
3. To help industry consultants, drug and diagnostics manufacturers, vendors and dealers align their market-centric strategies
4. To obtain research based business decision and add weight to presentations and marketing material
5. To gain competitive knowledge of leading players
6. To avail limited customization in the report without any extra charges and get research data or trends added in the report as per the buyer's specific needs

Company Profiling
Galmed Pharmaceuticals
Genfit
Galectin Therapeutics
Gilead SciencesHologic Inc.

Contact Us:                          
Call: +1-646-491-9876
Email:  [email protected]

Posted by Rajat Sahni on Thursday November 16 2017, 6:06 AM EST. All trademarks acknowledged. Filed under Uncategorized. Comments and Trackbacks closed. Follow responses: RSS 2.0